Colorectal Cancer
Rottapharm Biotech S.r.l. is active in metastatic colorectal cancer, with a focus on mismatch-repair-proficient and microsatellite stable disease after prior treatment.
- pMMR and MSS metastatic colorectal cancer
- Pretreated advanced gastrointestinal malignancy
- Immuno-oncology combinations
The sponsor’s research interest in this area centres on advanced colorectal cancer where standard immune responsiveness is limited, with attention to therapeutic strategies that may expand treatment options in resistant disease.
Other Metastatic Gastrointestinal Cancers
The sponsor also supports research in metastatic GI cancers beyond colorectal disease, reflecting interest in broader gastrointestinal oncology settings.
- Metastatic GI malignancies
- Advanced solid tumours
- Checkpoint inhibitor-based therapy
This area includes malignancies with shared clinical challenges such as metastatic spread, prior treatment exposure, and the need for disease control in later-line care.
Immuno-Oncology
Rottapharm Biotech S.r.l. shows a clear therapeutic interest in immuno-oncology, particularly combinations involving PD-1 inhibition.
- PD-1 inhibitor combinations
- Immune checkpoint blockade
- Combination cancer therapy
The funded research is directed toward evaluating how immune-based treatment strategies may be applied in tumours with limited responsiveness to single-agent approaches.
Oncology Safety and Efficacy Assessment
The sponsor’s clinical research includes evaluation of safety, tolerability, and early antitumour activity in advanced cancer populations.
- Safety and tolerability
- Preliminary efficacy
- Disease control and objective response
These interests align with the development of treatment options for patients with metastatic disease who have already received prior therapy.
